Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
1.52
Dollar change
+0.14
Percentage change
10.14
%
Index- P/E- EPS (ttm)- Insider Own0.93% Shs Outstand4.35M Perf Week-7.88%
Market Cap6.61M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.31M Perf Month16.92%
Income- PEG- EPS next Q-0.54 Inst Own7.07% Short Float0.63% Perf Quarter-5.59%
Sales- P/S- EPS this Y24.55% Inst Trans0.56% Short Ratio0.06 Perf Half Y0.00%
Book/sh2.42 P/B0.63 EPS next Y- ROA- Short Interest0.03M Perf Year-26.21%
Cash/sh2.72 P/C0.56 EPS next 5Y- ROE- 52W Range0.99 - 4.30 Perf YTD5.56%
Dividend Est.- P/FCF- EPS past 5Y-25.04% ROI- 52W High-64.65% Beta0.61
Dividend TTM- Quick Ratio7.63 Sales past 5Y- Gross Margin- 52W Low53.54% ATR (14)0.13
Dividend Ex-Date- Current Ratio7.63 EPS Y/Y TTM26.64% Oper. Margin0.00% RSI (14)58.38 Volatility10.70% 9.25%
Employees- Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price5.25
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q72.23% Payout- Rel Volume0.52 Prev Close1.38
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume491.03K Price1.52
SMA2014.29% SMA5013.81% SMA200-13.39% Trades Volume253,432 Change10.14%
Date Action Analyst Rating Change Price Target Change
Oct-15-19Initiated The Benchmark Company Speculative Buy $10
Mar-27-24 02:00PM
08:27AM
Mar-20-24 05:38AM
Mar-19-24 08:21AM
Feb-29-24 08:38AM
08:11AM Loading…
Feb-26-24 08:11AM
Feb-13-24 11:45AM
Jan-18-24 08:20AM
Dec-27-23 08:21AM
Dec-05-23 08:33AM
Nov-14-23 08:37AM
Nov-10-23 08:00AM
Oct-05-23 10:03AM
Oct-02-23 08:33AM
Sep-15-23 02:38PM
01:43PM Loading…
Sep-13-23 01:43PM
08:16AM
Sep-11-23 10:04AM
Sep-06-23 08:12AM
Aug-09-23 08:13AM
Jul-25-23 08:12AM
Jul-19-23 08:02AM
Jun-14-23 08:12AM
Jun-06-23 03:01PM
08:02AM
May-12-23 08:38AM
Apr-26-23 04:21PM
08:18AM
Mar-08-23 09:09AM
Feb-16-23 08:35AM
10:42AM Loading…
Feb-08-23 10:42AM
08:43AM
Jan-25-23 08:27AM
Jan-03-23 04:38PM
Dec-29-22 08:00PM
09:08AM
08:45AM
Dec-01-22 10:45AM
Nov-09-22 12:38PM
Oct-31-22 11:39AM
09:57AM
Oct-24-22 04:15PM
Sep-20-22 09:05AM
Sep-06-22 08:21AM
Aug-16-22 03:00PM
Aug-12-22 01:48PM
Jul-12-22 02:24PM
10:26AM
Jun-29-22 01:25PM
Jun-21-22 12:30PM
Jun-15-22 12:30PM
Jun-09-22 08:18AM
May-06-22 09:02AM
May-03-22 08:09AM
Apr-19-22 03:29PM
10:29AM
Apr-14-22 01:02PM
Apr-12-22 08:17AM
Apr-11-22 11:31PM
04:21PM
03:49PM
10:17AM
09:47AM
08:05AM
07:57AM
06:21AM
Apr-01-22 08:02AM
Mar-22-22 09:48AM
Mar-11-22 08:00AM
Feb-09-22 10:10AM
Feb-07-22 08:02AM
Jan-31-22 08:17AM
Jan-05-22 05:18AM
Jan-04-22 02:13PM
08:01AM
Dec-21-21 07:59AM
Dec-08-21 08:00AM
Nov-30-21 08:00AM
Nov-16-21 08:30AM
Nov-08-21 08:38AM
Oct-19-21 12:47PM
Oct-12-21 10:04AM
10:00AM
Sep-22-21 07:00AM
Sep-21-21 10:05AM
Sep-08-21 08:02AM
07:56AM
Aug-11-21 09:01AM
Aug-02-21 08:15AM
Jul-13-21 10:13AM
08:15AM
Jun-28-21 08:01AM
Jun-13-21 11:23PM
Jun-10-21 04:16AM
Jun-07-21 02:31PM
Jun-03-21 12:32PM
08:01AM
Jun-01-21 08:05AM
May-24-21 08:01AM
May-13-21 08:28AM
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.